Moderna (MRNA) has disclosed a new risk, in the Debt & Financing category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Failure by Moderna to comply with covenants under its Ares Capital–led credit agreement could trigger an event of default, allowing lenders to halt further funding and accelerate all outstanding debt, including interest and fees. If Moderna could not promptly repay these amounts, secured lenders could enforce on collateral, and there is no assurance that the value of its assets would be sufficient to cover the indebtedness in full.
The average MRNA stock price target is $35.73, implying -28.35% downside potential.
To learn more about Moderna’s risk factors, click here.